Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 4/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14267466 | 0.89 | AR (0.37) | ALDH1A1ARGAA | |
| SCHEMBL27777709 | 0.89 | AR (0.37) | ALDH1A1ARGAA | |
| SCHEMBL13108596 | 0.84 | AAK1 (0.37) | AAK1GLAALDH1A1TRPA1AR | |
| SCHEMBL13108606 | 0.84 | AAK1 (0.37) | AAK1GLAALDH1A1TRPA1AR | |
| SCHEMBL13108599 | 0.83 | AAK1 (0.36) | AAK1GLAALDH1A1TRPA1AR | |
| SCHEMBL13108597 | 0.78 | KDM4E (0.41) | AAK1GLAALDH1A1TRPA1AR | |
| SCHEMBL13108595 | 0.77 | STAT3 (0.35) | AAK1ALDH1A1ARCYP2C19S1PR3 | |
| SCHEMBL13108613 | 0.73 | MAPT (0.40) | GLAALDH1A1ARBLMKDM4E | |
| SCHEMBL28779023 | 0.73 | AR (0.43) | ALDH1A1ARGAA | |
| SCHEMBL13108620 | 0.73 | AR (0.43) | ALDH1A1ARGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816395-B2 | Pyrrolidinone anilines as progesterone receptor modulators | GLAXOSMITHKLINE LLC (US) | 2010-10-19 | — | — | US | disclosed |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-08-19 | — | — | US | disclosed |
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | GLAXOSMITHKLINE LLC | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039517-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | AAK1 1884/4885HDAC8 626/4885GLA 3692/4885 |
| US-20100210706-A1 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS | PGR, PGRMC2, PGRMC1 | AAK1 1884/4885HDAC8 626/4885GLA 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.